Disease · EFO_0010702

opioid use disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. opioid use disorder. Diseases, record EFO_0010702. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0010702

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: opioid use disorder
Open Targets ID: EFO_0010702
Highest stage of its drugs: Phase 3, for 12 of its 64 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs64

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUPRENORPHINE	CHEMBL511142	Small molecule	Phase 3	ClinicalTrials.gov	69	69	69	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Phase 3	ClinicalTrials.gov	21	21	21	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 3	ClinicalTrials.gov	11	11	10	Drugs and targets
METHADONE	CHEMBL651	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
NALOXONE	CHEMBL80	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
DRONABINOL	CHEMBL465	Small molecule	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets
MORPHINE	CHEMBL70	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FALLYPRIDE	CHEMBL392158	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
KETAMINE HYDROCHLORIDE	CHEMBL1714	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
OPIUM	CHEMBL2107914		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 64

See all 64 drugs

Targets73

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	12	Mu opioid receptor agonist; Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta antagonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	5	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3356	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	5	Serotonin 2c (5-HT2c) receptor agonist; Serotonin 2c (5-HT2c) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3358	Drugs and targets
OPRK1	Kappa-type opioid receptor	5	Kappa opioid receptor agonist; Kappa opioid receptor partial agonist; Opioid receptors; mu/kappa/delta antagonist	Phase 3	https://conductscience.org/library/genes/4986	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	4	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2/3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	4	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2/3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	4	Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2/3	https://conductscience.org/library/genes/152	Drugs and targets
DRD2	D(2) dopamine receptor	4	D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
OPRD1	Delta-type opioid receptor	4	Delta opioid receptor antagonist; Opioid receptors; mu/kappa/delta antagonist	Phase 3	https://conductscience.org/library/genes/4985	Drugs and targets
SLC6A2	Monoamine transporter	4	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent	Phase 2	https://conductscience.org/library/genes/6530	Drugs and targets

1 to 10 of 73

See all 73 targets

Trials157

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02510014	Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder	Phase 3	775	2018-03-29	Opioid Use Disorder, Opioid-related Disorders	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov
NCT02357901	Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine	Phase 3	665	2018-02-20	Opioid Dependence, Opioid Related Disorders	BUPRENORPHINE, NALOXONE	Its record names the disease	ClinicalTrials.gov
NCT02651584	Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence	Phase 3	428	2019-08-22	Opioid Use Disorders	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov
NCT02537574	Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)	Phase 3	380	2019-01-09	Opioid Use Disorder	BUPRENORPHINE, NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT02672111	Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder	Phase 3	228	2019-08-01	Opioid Use Disorder	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov
NCT02334215	A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail	Not applicable	225	2020-09-16	Opioid Use Disorder	METHADONE	Its record names the disease	ClinicalTrials.gov
NCT04470050	Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal	Phase 1/2	225	2023-10-26	Opioid Withdrawal	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov
NCT02896296	Open-Label Treatment Extension Study	Phase 3	208	2018-11-02	Opioid Use Disorder, Opioid-related Disorders	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov
NCT02110264	Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)	Phase 3	151	2020-01-22	Opioid Use Disorders	NALTREXONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02617628	Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone	Phase 2/3	146	2020-04-15	Opiate Dependence	NALTREXONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 157

See all 157 trials

Comparisons in its trials63

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
De Novo Subjects vs Roll-over Subjects: deaths from any cause	0 of 412	0 of 257	669	NCT02510014	Trial comparisons
De Novo Subjects vs Roll-over Subjects: serious adverse events	16 of 412	9 of 257	669	NCT02510014	Trial comparisons
Group 1: SL BPN/NX Tablets + Placebo SC Injections vs Group 2: CAM2038 SC Injections + SL Placebo Tablets: deaths from any cause	0 of 215	1 of 213	428	NCT02651584	Trial comparisons
Group 1: SL BPN/NX Tablets + Placebo SC Injections vs Group 2: CAM2038 SC Injections + SL Placebo Tablets: serious adverse events	16 of 215	5 of 213	428	NCT02651584	Trial comparisons
CAM2038 q1w or q4w With Prior Exposure to SL BPN/NX vs CAM2038 q1w or q4w New to BPN Treatment: deaths from any cause	0 of 190	0 of 37	227	NCT02672111	Trial comparisons
CAM2038 q1w or q4w With Prior Exposure to SL BPN/NX vs CAM2038 q1w or q4w New to BPN Treatment: serious adverse events	13 of 190	2 of 37	227	NCT02672111	Trial comparisons
Before Re-entry vs After Re-entry: deaths from any cause	1 of 74	3 of 72	146	NCT02617628	Trial comparisons
Before Re-entry vs After Re-entry: serious adverse events	10 of 74	13 of 72	146	NCT02617628	Trial comparisons
Extended-release Naltrexone (XR-NTX) vs Treatment as Usual (TAU): deaths from any cause	2 of 55	1 of 59	114	NCT03275350	Trial comparisons
Extended-release Naltrexone (XR-NTX) vs Treatment as Usual (TAU): serious adverse events	5 of 55	7 of 59	114	NCT03275350	Trial comparisons

1 to 10 of 63

See all 63 comparisons in its trials

Papers from its trials88

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39534517	RESULT	1	PubMed
38624259	RESULT	1	PubMed
38045803	RESULT	1	PubMed
33972795	RESULT	1	PubMed
33601929	RESULT	1	PubMed
33428284	RESULT	1	PubMed
32098487	RESULT	1	PubMed
31681040	RESULT	1	PubMed
31065731	RESULT	1	PubMed
30944474	RESULT	1	PubMed

1 to 10 of 88

See all 88 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0010702

GET https://conductscience.org/api/diseases/v1/EFO_0010702/drugs?page=2

API reference For AI assistants